Extra Vitamin D can restore good bacteria in the gut, according to a study on mice, giving hope in the fight against risk factors for diabetes and heart disease.
Scientists have now discovered that Vitamin D deficiency is necessary for this syndrome to progress in mice, with underlying disturbances in gut bacteria.
The study, published in the journal Frontiers in Physiology, found that an insufficient supply of Vitamin D aggravates the imbalance in gut flora, contributing to full-scale fatty liver and metabolic syndrome.
If these findings can be validated in humans, sun bathing and Vitamin D supplements may be feasible and affordable approaches to improve or even prevent metabolic syndrome.
"Based on this study, we believe that keeping Vitamin D levels high, either through sun exposure, diet or supplementation, is beneficial for prevention and treatment of metabolic syndrome," said Professor Stephen Pandol from Cedars-Sinai Medical Centre in the US.
The main cause of metabolic syndrome appears to be a diet high in fat or carbohydrate.
However, observational studies have also linked metabolic syndrome to Vitamin D deficiency, which affects 30 to 60 percent of the world's population.
The research team made important advances in understanding the causative role of Vitamin D in this syndrome.
"A sufficient dietary Vitamin D supplement can partially but significantly antagonise metabolic syndrome caused by high fat diet in mice," says Pandol.
"These are amounts equivalent to the dietary recommendations for humans."
More specifically, they have shown that a high fat diet affects the balance between good and bad bacteria in the gut. This induces modest fatty liver and slightly raises blood sugar levels in mice.
Vitamin D deficiency decreases the production of defensins, which are anti-microbial molecules essential to maintain healthy gut flora. As expected, an oral supply of a synthetic defensin recovers gut bacteria balance, decreases blood sugar levels and improves fatty liver.
Accordingly, Vitamin D supplementation improves metabolic syndrome in mice. The next step would be to validate the results in humans.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
